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Abstract
Objective. MTX remains the cornerstone for therapy for RA, yet research shows that non-adherence is significant
and correlates with response to therapy. This study aimed to halve self-reported non-adherence to MTX at the
Kellgren Centre for Rheumatology.
Methods. An anonymous self-report adherence questionnaire was developed and data collected for 3 months prior
to the introduction of interventions, and then regularly for the subsequent 2.5 years. A series of interventions were
implemented, including motivational interviewing training, consistent information about MTX and development of a
summary bookmark. Information on clinic times was collected for consultations with and without motivational inter-
viewing. Surveys were conducted to ascertain consistency of messages about MTX. A biochemical assay was
used to test MTX serum levels in patients at two time points: before and 2.8 years following introduction of the
changes. Remission rates at 6 and 12 months post-MTX initiation were retrieved from patient notes and cost
savings estimated by comparing actual numbers of new biologic starters compared with expected numbers based
on the numbers of consultants employed at the two time points.
Results. Between June and August 2016, self-reported non-adherence to MTX was 24.7%. Following introduction
of the interventions, self-reported non-adherence rates reduced to an average of 7.4% between April 2018 and
August 2019. Clinic times were not significantly increased when motivational interviewing was employed.
Consistency of messages by staff across three key areas (benefits of MTX, alcohol guidance and importance of
adherence) improved from 64% in September 2016 to 94% in January 2018. Biochemical non-adherence reduced
from 56% (September 2016) to 17% (June 2019), whilst remission rates 6 months post-initiation of MTX improved
from 13% in 2014/15 to 37% in 2017/18, resulting is estimated cost savings of £30 000 per year.
Conclusion. Non-adherence to MTX can be improved using simple measures including focussing on the adher-
ence and the benefits of treatment, and providing consistent information across departments.
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Rheumatology key messages
. MTX adherence can be improved in clinical practice to improve outcomes in inflammatory arthritis.
. Motivational interviewing and consistent messaging by clinicians and health-care professionals are effective
strategies.
. Drug education that focuses on both benefits and harms of MTX improves adherence.
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Introduction
Early intervention improves long-term outcomes in
patients with RA, with data from inception longitudinal
cohorts showing that effective treatment within the first
6 months of diagnosis is associated with better out-
comes after 20 years of follow-up [1]. MTX remains the
cornerstone for therapy for RA and is recommended as
first-line treatment by national and international organi-
zations [2, 3]. Clinical trials where MTX is used as the
comparator arm consistently show response rates of
80% of patients achieving good or moderate EULAR re-
sponse rates by 6 months in early RA; by contrast a re-
cent real-world study reported a lower response rate of
57% [4–7]. A drug cannot be effective if it is not taken,
and issues of non-adherence are recognized for all
chronic conditions [8]. Non-adherence is defined by the
World Health Organization as ‘the extent to which the
patient’s behaviour – taking medication, following a diet,
and/or executing lifestyle changes, corresponds with
agreed recommendations from a health-care provider.’
Previous research shows that non-adherence to MTX is
considerable, and correlates with response to therapy
(reviewed in [9]). Given that failure to respond to conven-
tional synthetic DMARDs is part of the eligibility criteria
for biologic therapies in the UK, and given the cost dif-
ferential of MTX compared with biologic drugs, there is
a health economic argument to optimize adherence to
MTX in order to achieve individual health benefits as
well as to reduce health costs. Furthermore, concomi-
tant MTX use and higher dose MTX is associated with
improved drug survival and lower frequency of anti-drug
antibodies in biologic-treated patients [10], further sup-
porting the need to optimize MTX adherence.
We aimed to use a quality improvement programme
to halve self-reported non-adherence to MTX at a single,
specialist rheumatology centre. We used both self-
report and a biochemical assay of serum MTX levels to
assess adherence over a 3-year period.
Methods
A multidisciplinary team comprising two consultant rheu-
matologists (A.B. and R.G.), an academic clinical lecturer
in rheumatology (M.J.), a health psychologist (C.B.) and a
senior specialist nurse (M.A.) underwent Health
Foundation training in quality improvement methods over
a 12-month period. Improvement Science for Leaders
(IS4L) is a bespoke programme to support clinical aca-
demics and health-care professionals to close the gap
between research and clinical practice by providing train-
ing in improvement science (www.haelo.org.uk).
An anonymous self-report questionnaire was developed
to capture information on non-adherence specific to all
patients taking MTX. This was adapted from a validated
questionnaire and developed with patient involvement
and subject to three Plan-Do-Study-Act (PDSA) cycles
[10]. Patients reporting to the receptionist were asked if
they were taking MTX and, if so, were asked to complete
the form and return it anonymously to the care centre.
Data were collected for 3 months prior to the introduction
of interventions, then monthly for the subsequent 2 years
and less frequently for the third year. Following discus-
sions with medical, nursing, pharmacy and patient col-
leagues, a series of interventions were developed:
. Process map: process mapping was undertaken to
understand the pathway from the clinical decision to
prescribe MTX to the patient being established on ther-
apy. From this, points in the pathway that were potential
barriers to adherence were identified.
. Motivational interviewing (MI): training was organized
for all permanent members of staff with refresher You-
tube training commissioned (https://www.youtube.
com/channel/UCoyHTp8AMW5-UjxfmqcVHiQ). MI is a
patient-centred consultation technique designed to
elicit the patient’s own goals and plans for behaviour
change [11].
. Personalized approach to tackling MTX concerns: at
the point of decision about starting MTX, clinicians
could flag on the drug education referral form if they
had initial concerns regarding non-adherence specific
to the patient. This allowed addressing the appropriate
raised issues in more detail during the 1:1 drug educa-
tion consultation. Clinicians were given the following
choices on the form:
a. Patient seems anxious (not taking in information/conversa-
tion jumping around)
b. Not convinced patient believes this is the right treatment
c. Patient concerned about side effects
d. I have no concerns and am sure that this patient will have
no issues with non-adherence
. A theory informed ‘agenda-setting’ tool was developed,
following three PDSA cycles, in order to focus consulta-
tions and ensure that adherence was addressed
directly.
. ‘What happens next’ sheet: a flowchart for patients was
developed following three rounds of PDSA to provided
clearer information about progression through the pre-
scribing pathway once MTX was commenced. It
included contact numbers in case of difficulty obtaining
MTX prescriptions, as these are prescribed from the
hospital until patients are established on a stable dose
of MTX according to shared care protocols (http://
gmmmg.nhs.uk).
. Drug education: MTX patient education slides were ex-
tensively revised to include positive messages about
the benefits of treatments, information on absolute risks
of adverse events as well as strategies to improve ad-
herence through identified barriers to taking MTX regu-
larly. Six PDSA cycles were undertaken before a final
slide set was agreed.
. Points to remember for MTX: six education points were
agreed within the core and wider clinical team, as being
imperative for patients to remember about MTX. A sum-
mary bookmark containing the main points to remem-
ber about MTX was developed following three PDSA
cycles to be handed to patients at the time they
received their MTX drug education from the nursing
team. These points were also included on laminated
sheets in clinic rooms and in the junior doctors’ office to
re-inforce the consistent messaging. Additionally, a
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banner was made with these points in the waiting area,
to promote a culture for openly talking about adherence
and any concerns about MTX.
. Maintaining long-term momentum: a series of regular
meetings with all consultant, nursing and pharmacy col-
leagues were held, during which consensus was
reached on information to be provided to patients to en-
sure consistency of messages by all clinical team mem-
bers. The core team met on a weekly basis to discuss
monthly data, patient feedback, plan/revise strategies
as required and keep up the momentum of introducing
a culture of improving adherence to medicines in the
department.
Outcomes
Our primary outcome was self-reported non-adherence,
as measured by anonymous surveys. A classification of
adherent was given if the MTX tablet or injection was
administered by the patient on the day agreed with the
health care professional. If the patient had paused treat-
ment due to being on an antibiotic whilst experiencing
an infection for instance, they were classed as adherent
(as would be consistent with the recommendations from
the health-care provider).
Information on length of clinic reviews was collected
for consultations with and without MI as a balancing
measure to determine whether using MI approach and
techniques increased consultation times. Surveys were
conducted for all medical and nursing staff at four points
during the 3 year process asking about information pro-
vided when talking to patients about MTX, in order to
determine whether message consistency was improved.
Prior to introducing interventions, blood samples from
20 consecutive patients receiving oral MTX were col-
lected in October 2016 and samples from 21 patients
collected in June 2019. Patients were asked verbally if
they had taken their MTX, and the day and dose. The
samples were tested for MTX levels using a mass spec-
trometry method developed by our group [12] to provide
an objective measure of adherence behaviour; this test
is not in routine clinical use and patients were not told
that the purpose of the blood sampling was to measure
MTX drug levels.
An audit of DAS28 scores by 6 and 12 months follow-
ing MTX initiation was carried out for patients starting
therapy up until 2016 and compared with patients initiat-
ing therapy between May 2017 and April 2018. The num-
ber of patients starting a biologic for the first time was
retrieved from a biologics prescribing database for 2014
and 2015. The number of new starters was averaged
according to the number of whole-time equivalent consul-
tants. Assuming a constant prescribing rate per whole-
time equivalent consultant, the expected number of new
biologic starters was estimated for 2018 and 2019 and
compared with actual numbers of new starters.
Manchester University National Health Service (NHS)
Trust R&I Department approved the study as a Quality
Improvement (QI) project, and no other ethical approval
was necessary.
Results
The process map for MTX prescribing is shown in supple-
mentary Fig. S1, available at Rheumatology online. MI
training was conducted in September 2016 with a face-
to-face refresher organized in April 2017, along with re-
minder YouTube videos available from December 2017.
The agenda setting tool developed was not found to be
helpful by patients and so was discarded. Following
meetings with clinical colleagues, the six main points to
be conveyed to patients by all staff were agreed and
were used to populate a bookmark reminder for patients
(Fig. 1). The most common self-reported reasons for non-
adherence were forgetting and stopping due to an infec-
tion such as a cold. Patient education slides were subse-
quently amended in two ways. Firstly, information was
given on how to set Smartphone reminders with details
of Smartphone apps to help manage medications for
those on multiple drug treatment; and secondly, not
needing to discontinue MTX treatment for coughs/colds/
viral infections was reinforced in the slide set. Patients
were recommended to stop MTX only if they were pre-
scribed an antibiotic for an infection.
Table 1 shows the number of forms collected in each
3 month period and the number reporting non-adherence.
Between June and August 2016, mean self-reported non-
adherence to MTX was 24.7%, consistent with previous
reports [9]. Post-interventions, self-reported non-
adherence rates had reduced to an average of 7.4% in
the 17months between April 2018 and August 2019
(Fig. 2). Clinic times were not significantly increased when
MI was employed (data not shown). Consistency of mes-
sages by staff across three key areas (benefits of MTX, al-
cohol guidance and importance of adherence) improved
from 64% in September 2016 to 94% in January 2018
(supplementary Fig. S2, available at Rheumatology online).
Of the 20 consecutive participants taking MTX recruited
for biochemical testing in October 2016, two reported
non-adherence, equating to 10% self-reported non-adher-
ence. The two patients self-reporting non-adherence were
confirmed as biochemically non-adherent (negative pre-
dictive value ¼ 100%). Ten out of the 18 who reported
they were adherent were identified as biochemically non-
adherent (56% non-adherence). In the second round of
testing following introduction of the QI interventions in
June 2019, 21 patients receiving oral MTX were tested. Of
these, three reported non-adherence, equating to 14%
self-reported non-adherence, and all three were all cor-
rectly identified as biochemically non-adherent (negative
predictive value¼100%). Three out of the 18 who
reported that they were adherent were identified as bio-
chemically non-adherent (17% non-adherence).
For patients initiating MTX prior to 2016, 8/61 (13%)
patients achieved remission (DAS28 <2.6) by 6months and
12/58 (21%) by 12months. This compared with 20/54
(37%) and 20/43 (46%), respectively, for patients initiating
MTX between May 2017 and April 2018. There were 135
expected new starters for first biologic drugs in 2018/19
but only 105 actual new starters, meaning 10 fewer starters
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than expected each year. Using public data for drug costs
and assuming all new starters would receive a biosimilar
drug, estimated cost savings were >£30 000 per year.
Discussion
We have shown that non-adherence to MTX can be
improved using a series of measures including asking
about adherence, increasing the focus on the benefits of
treatment and providing consistent information across a
single department. We used a mixed-methods approach
to quantify improvements in adherence in the absence
of a standardized method to demonstrate improvement.
By using a combination of personalized and population-
level approaches and maintaining momentum through
regular meetings, we were able to demonstrate long-
term sustained improvements over a 3-year period.
Strengths of the study include the long follow-up post-
introduction of interventions demonstrating maintenance
over 2 years following the year-long implementation
phase. Furthermore, using an objective biochemical
assay as well as patient self-report has confirmed this
sustained improvement. We measured consultation times
with and without the use of MI and showed that it did not
significantly increase the length of appointments. The
interventions employed were informed by patient involve-
ment, health psychology theory and previous research
[13]. For example, anxiety has previously been reported
to correlate with subsequent non-adherence to MTX, so
we addressed this by adapting nurse education referral
forms to highlight patients who seem anxious about start-
ing the treatment [7].
Limitations include that, first, due to a lack of a pre-
scribing database before the introduction of these inter-
ventions, we have not been able to show that improved
adherence translates to increased persistence on MTX;
however, we have identified fewer new starters on bio-
logic drugs than would be expected. Furthermore, previ-
ous studies have consistently reported that non-
adherence correlates with subsequent poorer response
[9] and we have found more that patients achieved re-
mission at 6 and 12 months following the interventions,
suggesting better outcomes. These data only relate to
patients initiating MTX and the lack of a prescribing
database at the outset of the project means we do not
have similar information for patients established on
MTX. Second, this QI programme was carried out in a
single centre and the pathways and interventions
described may not be directly translatable to other NHS
clinics. However, initial non-adherence rates are consist-
ent with previous reports, which estimate that at least
one in four people with long-term conditions do not take
their medication as prescribed. We have created a re-
source pack that could be adapted by other centres
(https://www.musculoskeletal.manchester.ac.uk/); this is
currently being trialled in two other UK NHS Trusts. In
particular, it should be noted that the advice given about
alcohol and MTX differs from that in some other guid-
ance; we recommend a maximum of 6 units per week,
and this consensus was reached to mitigate against the
concerns of medical staff about the impact of combined
MTX and alcohol on liver function. It is important to rec-
ognize that the population screened for adherence was
not the same at each time point; hence, we cannot say
for certain which of any specific intervention was re-
sponsible for the decrease, which would therefore sug-
gest that the package of interventions should be used if
FIG. 1 Bookmark handed to patients highlighting key
points regarding MTX
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implementing at other centres. The process for initiating
MTX will differ across settings and so not all the sug-
gestions will be appropriate; for example, few centres
have a virtual DMARD clinic and so the approach of
highlighting concerns about adherence when initiating
MTX via the virtual DMARD form will require a different
approach. The Hawthorne effect of behaviour modifica-
tion as a result of being observed is likely to have
played a role in improving adherence rates, and one of
the most important culture changes in the department
was that clinicians asked about adherence more often;
indeed, previous research related to hand washing
shows that observation alone can be very effective [14].
We see this as a positive benefit, as the results show
that improved adherence correlated with improved re-
mission rates over the same time periods. Finally, this
work was restricted to MTX adherence, but the same
process could be applied to other drugs where non-
adherence is a potential issue; for example, a previous
UK study showed 27% non-adherence to biologic thera-
pies [15].
The use of the biochemical test of MTX drug levels
confirmed objectively that non-adherence rates fell: from
56% to 17% between the two time points in 2016 and
TABLE 1 Number of non-adherent patients between June 2016 and August 2019
Time frame Number of forms Non-adherent Percentage non-adherence
June–August 2016 73 18 24.7
September–November 2016 44 4 9.1
December 2016–February 2017 59 10 16.9
March–May 2017 52 12 23.1
June–August 2017 44 6 13.6
September–November 2017 63 8 12.7
December 2017–March 2018 43 6 13.9
April–June 2018 75 6 8
July–September 2018 25 2 8
October 2018–January 2019 22 2 9.1
January–August 2019 39 2 5.1
Total 539
A total of 539 forms were collected between June 2016 and August 2016 representing a random sample of patients on
MTX. The data are presented in 3-month intervals. However, sampling periods were longer towards the end of the study,
reflecting when the forms were collected.
FIG. 2 Self-reported non-adherence to MTX in rheumatology outpatients
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2019. It is interesting that self-reported non-adherence
was lower than that detected biochemically before the
introduction of the interventions (56% biochemical non-
adherence vs 24% self-report) and even after the QI
interventions, 17% who self-reported to be adherent
were biochemically non-adherent. The assay has been
validated and found to be 95% sensitive, but we cannot
exclude measurement error as a cause for the discrep-
ant results; however, the fact that biochemical and self-
report adherence has improved shows that adherence
behaviour has changed since the introduction of the
programme. The testing of blood samples was per-
formed only at the two time points described, which
were over 30 months apart, and patients were not told
that the blood would be tested for MTX drug levels; it is
unlikely therefore that performing the blood test was re-
sponsible for the change in adherence.
In hypertension management, biochemical testing of
urine for commonly prescribed anti-hypertensives has
been reported to improve adherence, improve control of
blood pressure and to result in health economic benefits
[16]. This QI project shows that adherence can also be
improved by comprehensively tackling multiple points in
the prescribing pathway to remove and address barriers to
adherence; ultimately, this may have health economic
implications by delaying progression to biologic or targeted
therapies, and improving drug survival and subsequent pa-
tient outcomes in those requiring such treatments.
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